MX9702616A - Isoforma intracelular del antagonista receptor de interleucina -1. - Google Patents

Isoforma intracelular del antagonista receptor de interleucina -1.

Info

Publication number
MX9702616A
MX9702616A MX9702616A MX9702616A MX9702616A MX 9702616 A MX9702616 A MX 9702616A MX 9702616 A MX9702616 A MX 9702616A MX 9702616 A MX9702616 A MX 9702616A MX 9702616 A MX9702616 A MX 9702616A
Authority
MX
Mexico
Prior art keywords
interleukin
antagonist
receptor antagonist
new
intracellular isoform
Prior art date
Application number
MX9702616A
Other languages
English (en)
Inventor
Francesco Colotta
Marta Muzio
Alberto Mantovani
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MX9702616A publication Critical patent/MX9702616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)

Abstract

Se describe un nuevo antagonista de interleucina-1 contra tanto IL-1a como IL-B, una nueva secuencia de ADN que codifica el antagonista IL-1 y el método para obtener un antagonista de IL-1 mediante la técnica de ADN recombinante; también se describe el uso profiláctico, terapéutico y de diagnostico de tal nuevo antagonista IL-1 en patologías que se derivan de la produccion de IL-1.
MX9702616A 1994-10-13 1995-10-12 Isoforma intracelular del antagonista receptor de interleucina -1. MX9702616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI942097A IT1270662B (it) 1994-10-13 1994-10-13 Antagonista della interleuchina-1
PCT/EP1995/004023 WO1996012022A1 (en) 1994-10-13 1995-10-12 Intracellular isoform of the interleukin-1 receptor antagonist

Publications (1)

Publication Number Publication Date
MX9702616A true MX9702616A (es) 1998-04-30

Family

ID=11369705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702616A MX9702616A (es) 1994-10-13 1995-10-12 Isoforma intracelular del antagonista receptor de interleucina -1.

Country Status (19)

Country Link
US (1) US5739282A (es)
EP (1) EP0786002B1 (es)
JP (1) JPH10509306A (es)
KR (1) KR100237936B1 (es)
CN (2) CN100363053C (es)
AT (1) ATE303439T1 (es)
BR (1) BR9509317A (es)
CA (1) CA2202470C (es)
DE (1) DE69534419T2 (es)
EE (1) EE03697B1 (es)
ES (1) ES2243942T3 (es)
HK (2) HK1002659A1 (es)
IT (1) IT1270662B (es)
MX (1) MX9702616A (es)
NO (1) NO320494B1 (es)
PT (1) PT786002E (es)
RU (1) RU2193064C2 (es)
UA (1) UA65522C2 (es)
WO (1) WO1996012022A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
PT938500E (pt) 1996-10-31 2005-02-28 Applied Research Systems Peptidos inibidores da ice
DE69738948D1 (de) * 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL126562A0 (en) * 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
ES2533084T3 (es) * 2003-12-23 2015-04-07 Genentech, Inc. Tratamiento del cáncer con anticuerpos monoclonales anti-IL 13 novedosos
EP2327413A1 (en) 2004-07-06 2011-06-01 ZymoGenetics, Inc. Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
WO2009062339A1 (en) 2007-11-14 2009-05-22 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
CA2828504A1 (en) 2011-03-14 2012-09-20 Serodus Asa Antagonists of the interleukin-1 receptor
DK2859015T3 (en) 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
ES2103305T3 (es) * 1989-11-29 1997-09-16 Amgen Boulder Inc Produccion de inhibidor de interleuquina-1 humana recombinada.
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
WO1991017249A1 (en) * 1990-05-01 1991-11-14 Cetus Corporation Interleukin-1 antagonist and uses thereof

Also Published As

Publication number Publication date
NO971624D0 (no) 1997-04-09
EE03697B1 (et) 2002-04-15
EE9700090A (et) 1997-10-15
DE69534419D1 (de) 2005-10-06
NO971624L (no) 1997-05-30
CA2202470A1 (en) 1996-04-25
RU2193064C2 (ru) 2002-11-20
BR9509317A (pt) 1997-10-14
CN100363053C (zh) 2008-01-23
EP0786002B1 (en) 2005-08-31
IT1270662B (it) 1997-05-07
ATE303439T1 (de) 2005-09-15
KR970706391A (ko) 1997-11-03
KR100237936B1 (ko) 2000-01-15
AU701471B2 (en) 1999-01-28
ITMI942097A0 (it) 1994-10-13
DE69534419T2 (de) 2006-06-14
WO1996012022A1 (en) 1996-04-25
UA65522C2 (en) 2004-04-15
CN1224707C (zh) 2005-10-26
US5739282A (en) 1998-04-14
ITMI942097A1 (it) 1996-04-13
JPH10509306A (ja) 1998-09-14
CN1679919A (zh) 2005-10-12
EP0786002A1 (en) 1997-07-30
CN1161058A (zh) 1997-10-01
CA2202470C (en) 2008-09-16
HK1002659A1 (en) 1998-09-11
PT786002E (pt) 2005-11-30
ES2243942T3 (es) 2005-12-01
HK1081124A1 (en) 2006-05-12
NO320494B1 (no) 2005-12-12
AU3841795A (en) 1996-05-06

Similar Documents

Publication Publication Date Title
HK1081124A1 (en) Intracellular isoform of the interleukin-1 receptor antagonist
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
CA2198603A1 (en) Use of Stem Cell Factor and Soluble Interleukin-6 Receptor for the Ex Vivo Expansion of Hematopoietic Multipotential Cells
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
IL108503A0 (en) Self leveling membrane test probe
ES8307899A1 (es) "un metodo para detectar sangre humana oculta en muestras de deposicion humana".
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
EP1029916A4 (en) HUMAN LYSOPHOSPHATIDE ACID RECEPTOR AND USE OF SAID RECEPTOR
EP0652358A3 (de) Verfahren zur Überprüfung der Funktionsfähigkeit von Lambdasonden.
WO2001089549A3 (en) Therapeutic uses of il-1 receptor antagonist
EP1111049A4 (en) NOVEL RECEPTOR PROTEIN AND METHOD FOR DIAGNOSING INFLAMMATORY DISEASES USING THE SAME
EP1443055A3 (en) Interleukins-21 and 22
FR2653445B1 (fr) Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
IT1238069B (it) Procedimento per la preparazione di un diaframma completamente di carbonio da usare in apparecchiature acustiche
WO2000028034A3 (en) Cytokine signal regulators
AU6189486A (en) Monoclonal antibodies to prosomal proteins
WO1998041538A3 (en) Novel human cytokine/steroid receptor protein
DE9413830U1 (de) Liege- oder Sitzmöbel für an Inkontinenz leidende Personen
AU2688395A (en) The use of sialic acid determination for determining alcohol consumption
ITCT920022A0 (it) Test immunoenzimatico competitivo per il rilievo quantitativo del frammento secretorio presente nel siero, nella saliva, nell'urina, nelle lacrime, nel succo gastrico, nel secreto vaginale, nelle feci.
DE29707771U1 (de) Einrichtung zur Bestimmung von endexpiratorischen Gasen, insbes. für die Ovulationszeitpunktbestimmung
IT1277556B1 (it) Dispositivo di raccordo regolabile e amovibile, particolarmente adatto per contatori del gas e simili
DE227102T1 (de) Errichtete zellinie aus menschlichem normalem gebaermuttermuskel, verfahren zur herstellung des plasminogenaktivators mittels dieser zellinie und plasminogenaktivator.
IT8920060A0 (it) Impianto per la riduzione di pressione del gas metano tra le centrali di pompaggio e le reti di distribuzione all'utenza.
IT8841683A0 (it) Dispositivo oftalmologico in particolare per l'asportazione di umore vitreo, cateratte molli e membrane preretinali.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: LABORATOIRES SERONO SA

MM Annulment or lapse due to non-payment of fees